The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Debate: anti-CD38-VRd quads versus anti-CD38-KRd quads in newly diagnosed myeloma
In this video, Lisa Leypoldt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, provides insight into a debate on anti-CD38-VRd quadruplets versus anti-CD28-KRd quadruplet combinations for treating patients with newly diagnosed multiple myeloma (MM). Dr Leypoldt emphasizes that KRd quadruplet regimens are a superior choice for high-risk patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
